Amlodipine/perindopril - Servier
Alternative Names: Acerycal; Amlodipine/perindopril; Bi-Prestarium; Calcertil; Co-Prestarium; Coveram; Covercard; Covercor; Coverlam; Coversical; Coversyl AM; Perindopril arginine/amlodipine besylate; Perindopril/amlodipine; Prestalia; Prestance; Prestarium-Co; Presteram; Prexanor; Proacertil; Procoversyl; Reaptan; S-05985; ViacoramLatest Information Update: 11 May 2021
Price :
$50 *
At a glance
- Originator Servier
- Developer Servier; Symplmed
- Class Antihypertensives; Dihydropyridines; Indoles; Small molecules; Vascular disorder therapies
- Mechanism of Action ACE inhibitors; Calcium channel antagonists; Cytochrome P-450 enzyme system inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Coronary artery disease; Hypertension
Most Recent Events
- 04 Jan 2021 Adhera Therapeutics terminates its licence for Perindopril/amlodipine in USA
- 14 Apr 2020 Perindopril/amlodipine - Servier is available for licensing in USA as of 31 Dec 2019. https://adherathera.com/
- 28 Jan 2019 Launched for Hypertension (Treatment-naive) in Canada, prior January 2019 (PO)